Pillar Biosciences Raises $34.5 Million to Accelerate Precision Medicine Innovation
In May 2025, Pillar Biosciences announced it had raised $34.5 million in funding, with participation from Illumina, Soleus Capital, and existing investors. The proceeds will be used to expand commercial activities, strengthen partnerships with biopharma companies, and accelerate the adoption of its distributable clinical testing kits worldwide. Pillar’s SLIMamp® and PiVAT® technology platforms enable highly sensitive, rapid, and cost-effective genomic profiling of tumors, empowering clinicians to make personalized therapy decisions. Illumina’s vice president noted that the partnership with Pillar advances global precision oncology by combining rapid NGS targeted panels with Illumina’s sequencing and bioinformatics solutions.
Related Posts
Antalpha Ventures, Web3Labs, and Goldford-HB Launch Computational Power Fund for AI and Web3 Projects
Antalpha Ventures, a global investment firm at the forefront of cutting-edge technology, has partnered with renowned Asian Web3 incubator Web3Labs and venture capital firm Goldford-HB to launch a new computational power fund. This fund aims to support early to mid-stage AI and Web3 projects worldwide by providing the necessary computational resources. Fund Back
MDHC Technologies Secures Series B Funding to Accelerate Growth and Innovation (2024)
MDHC Technologies completed a Series B funding round with investors including Chery Automobile, LAKSIMI Capital, Lucion Venture Capital Group, Yongxin Fangzhou, Addor Capital, and others. The funding will accelerate the development of its intelligent manufacturing platform, expand production capacity, and increase R&D investment, driving innovation and mark
Breakthrough in Quantum Measurement and Control System Technology (March, 2025)
Launched China’s first scalable low-latency feedback quantum control system ZW-QCS560 series, enabling “single-trigger multi-measurement” and rapid feedback control within 300 nanoseconds, solving critical quantum error correction challenges312. News Link : https://finance.sina.com.cn/jjxw/2025-03-05/doc-inenprwv9366586.shtml
NGS test completed in one day, lung and colon cancer test kits receive FDA approval
NGS (next generation sequencing technology), also known as high-throughput sequencing technology. It is commonly used for genetic disease screening, prenatal testing or diagnosis, oncology clinical diagnosis, pharmacogenomic testing, cancer chemotherapy and treatment, and single gene disease screening or diagnosis. It is capable of sequencing hundreds of thousa
Leave a Reply